Activity Preview

Live

Getting Started Building Your Clozapine Practice (Spring 2020)

Activity Type:

  • On Demand Plus


Release Date: 3/16/2020

Expiration Date: 6/28/2020

  • AMA PRA Category 1: 12
  • Participation: 12

Register

Overview

To enroll, enter group code "Clozapine2" on the purchase step. Space is limited. 

In order to increase appropriate use of clozapine, this 12-week virtual learning collaborative will focus on increasing appropriate use of clozapine to serve the needs of patients with serious mental illness.  Clozapine can be very rewarding to prescribe, since about half of patients get substantially better with clozapine, and this medication can result in major improvements in patients’ functioning and quality of life. This collaborative is for clinicians who want to prescribe more clozapine or build a clozapine program that they will direct. Through the course, enrollees will increase access to clozapine using the following steps: involve and gain support from members of a clozapine team, assess patient eligibility for clozapine, lead the care team for tracking of side effects and response and delivery of clozapine, ensure provision of education for patients or families, and routinely track panels of clozapine patients.  By the end of the learning collaborative, enrollees will have increased appropriate access to clozapine among their patient panel or the panels of clinicians who they supervise. They will have procedures in place that facilitate clozapine use on an ongoing basis, making clozapine as easy to prescribe as other psychotropic medications.

Program Schedule

The facilitated 12-week syllabus will be held from March 23, 2020 to June 14, 2020.

(Periodic video conferences are scheduled on Thursdays from 2-3pm ET)

Pricing

FREE - $0

Funding for this initiative was made possible (in part) by Grant No. 1H79SM080818-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. 

Learning Objectives

  • Identify patients who are appropriate candidates for clozapine
  • Describe team-based approaches to provision of clozapine
  • Explain how to provide clozapine safely and effectively

Target Audience

licensed psychiatrists, psychiatric mental health nurse practitioners, medical directors

Instructional Level

Intermediate

Estimated Time to Complete

Estimated Duration: 12 weeks; 12 hours
Program Begin Date: March 23, 2020
Program End Date: June 14, 2020
Credit Claim End Date: June 28, 2020

This course has a 12-week syllabus and is a collaborative learning experience, not independent study. 

Credit must be claimed within 14 days of the end of the last session. 

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the date of completion and hours earned.

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring CME activity for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Instructors/Planner

  • Alexander Young, MD. University of California, Los Angeles. Reports no financial relationships with commercial interests.   
  • Jonathan Meyer, MD, University of California, San Diego. Disclosure - Consultant: Acadia Pharmaceuticals, Alkermes, Abbvie, Intra-Cellular Therapies, Neurocrine; Speaker Bureau: Acadia Pharmaceuticals, Alkermes, Janssen Pharmaceutica, Neurocrine, Otsuka America, Inc., Sunovion Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.

Planners

  • Tristan Gorrindo, MD, American Psychiatric Association. Reports no financial relationships with commercial interests.   
  • Teri Brister, PHD, LPC, National Alliance for Mental Illness. Reports no financial relationships with commercial interests.   

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Hardware/Software Requierments

This course utilizes a variety of online resources and file types for its assignments. Please check that your device and network is compatible with the minimum requirements:

For additional technical issues or questions, please contact SMIadviserhelp@psych.org.

Register